R&D News | pharmaphorum

News

PureTech's Vedanta raises $27m for microbiome research

US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and

News

Novartis offers to buy Kymriah manufacturer

Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t

News

Merck takes a back seat on CAR-T, handing assets to Intrexon

Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies.

News

BMS confirms Taisho’s $1.6bn offer for UPSA

After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal

News

Pharma R&D productivity hits new low amid rising costs

Returns on pharma R&D investment are at a nine-year low, and the cost of developing a drug has nearly doubled since 2010, according to Deloitte’s yearly assessment of the industry’s pip

News

Sandoz joins medical cannabis drive with Tilray deal

Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray.

PureTech's Vedanta raises $27m for microbiome research

Novartis offers to buy Kymriah manufacturer

Merck takes a back seat on CAR-T, handing assets to Intrexon

BMS confirms Taisho’s $1.6bn offer for UPSA

Pharma R&D productivity hits new low amid rising costs

Sandoz joins medical cannabis drive with Tilray deal

Google Cloud launches Gemini for Healthcare

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks